A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer

Maria Q. Baggstrom, Yingwei Qi, Marianna Koczywas, Athanassios Argiris, Elizabeth A. Johnson, Michael J. Millward, Sara C. Murphy, Charles Erlichman, Charles M. Rudin, Ramaswamy Govindan

Research output: Contribution to journalArticle

102 Scopus citations

Abstract

Background: AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). Methods: Patients with recurrent "sensitive" SCLC (defined as no progression during and no disease recurrence <2 months after completion of first-line platinum-based chemotherapy) were eligible. AT-101 was administered 20 mg orally daily for 21 of 28 days each cycle for up to six cycles. The primary end point was the objective response rate. Results: At the time of planned interim evaluation, none of the 14 evaluable patients enrolled in the first stage had any response to therapy, and the study was closed permanently for further accrual. Three patients (21%) achieved stable disease after two cycles of therapy. Grade 3 toxicities included anorexia, fatigue, and nausea/vomiting. Conclusions: AT-101 is not active in patients with recurrent chemosensitive SCLC.

Original languageEnglish (US)
Pages (from-to)1757-1760
Number of pages4
JournalJournal of Thoracic Oncology
Volume6
Issue number10
DOIs
StatePublished - Oct 1 2011

Keywords

  • AT-101
  • Extensive-stage small cell lung cancer
  • Gossypol

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Baggstrom, M. Q., Qi, Y., Koczywas, M., Argiris, A., Johnson, E. A., Millward, M. J., Murphy, S. C., Erlichman, C., Rudin, C. M., & Govindan, R. (2011). A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. Journal of Thoracic Oncology, 6(10), 1757-1760. https://doi.org/10.1097/JTO.0b013e31822e2941